Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Testing the Ability of Immunotherapy to Alter the Tumor Immune MicroEnvionment (TIME) and Reduce or Eradicate High Risk DCIS

Next Previous
X
Search
Trial Profile

Testing the Ability of Immunotherapy to Alter the Tumor Immune MicroEnvionment (TIME) and Reduce or Eradicate High Risk DCIS

Status: Recruiting
Phase of Trial: Phase 0

Latest Information Update: 13 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MRNA 2752 (Primary) ; Pembrolizumab (Primary)
  • Indications Ductal carcinoma; Early breast cancer; HER2 positive breast cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 07 Jun 2024 Planned End Date changed from 31 Mar 2024 to 31 Mar 2025.
    • 07 Jun 2024 Planned primary completion date changed from 31 Mar 2024 to 31 Mar 2025.
    • 12 Sep 2023 Planned number of patients changed from 48 to 68.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top